Last updated: February 19, 2026
What is the Core Innovation of CA2595988?
Patent CA2595988, granted to Celgene Corporation, claims a method for treating a myelodysplastic syndrome (MDS). The primary innovation resides in the use of thalidomide in specific patient populations and dosages for this indication. The patent specifically covers the administration of thalidomide to MDS patients, particularly those with a specific cytogenetic abnormality, namely a deletion on chromosome 5 (del(5q)).
- Active Ingredient: Thalidomide
- Indication: Myelodysplastic Syndrome (MDS)
- Key Patient Subgroup: Patients with del(5q) chromosomal abnormality.
- Dosage Specificity: The patent details specific daily dosage ranges for thalidomide administration.
What are the Key Claims of CA2595988?
The patent's claims define the legal boundaries of its protection. For CA2595988, the most significant claims revolve around the method of treatment and the specific conditions under which it is to be applied.
Claim 1: This independent claim defines the core method. It claims "A method for treating a myelodysplastic syndrome in a patient comprising administering to the patient thalidomide."
Subsequent Claims (Examples):
- Claim 2: Claims the method of claim 1, wherein the myelodysplastic syndrome is a 5q-syndrome. The 5q-syndrome is characterized by the presence of a deletion on the long arm of chromosome 5.
- Claim 3: Claims the method of claim 2, wherein the patient has a cytogenetic abnormality of del(5q).
- Claim 4: Claims the method of claim 1, wherein the thalidomide is administered orally.
- Claim 5: Claims the method of claim 1, wherein the thalidomide is administered in a daily dose ranging from about 50 mg to about 400 mg.
- Claim 6: Claims the method of claim 5, wherein the daily dose is about 100 mg.
- Claim 7: Claims the method of claim 5, wherein the daily dose is about 200 mg.
- Claim 8: Claims the method of claim 1, wherein the thalidomide is administered daily.
- Claim 9: Claims the method of claim 1, wherein the thalidomide is administered for at least 28 days.
These claims, particularly those specifying the 5q-syndrome and specific dosage ranges, narrow the patent's scope to a targeted therapeutic application of thalidomide. The claims aim to protect the specific regimen and patient population for which thalidomide demonstrated efficacy in treating MDS.
What is the Patent Status and Term for CA2595988?
Understanding the patent's current status and remaining term is critical for market entry and investment decisions.
- Patent Holder: Celgene Corporation (now part of Bristol Myers Squibb).
- Application Filing Date: October 31, 2005
- Grant Date: November 27, 2012
- Patent Number: CA2595988
- Current Status: Expired. Canadian patents have a term of 20 years from the filing date. Therefore, CA2595988 expired on October 31, 2025.
The expiration of this patent removes a significant intellectual property barrier for the generic entry of thalidomide for the treatment of MDS in Canada.
What is the Technical Basis of CA2595988?
The patent is grounded in clinical research demonstrating thalidomide's efficacy in treating MDS, particularly in patients with the del(5q) abnormality. Thalidomide, a known immunomodulatory drug, has pleiotropic effects that are believed to contribute to its therapeutic action in MDS. These effects include:
- Anti-angiogenic properties: Inhibiting the formation of new blood vessels, which can be crucial for tumor growth.
- Immunomodulatory effects: Modulating the immune system's response, potentially reducing inflammatory processes contributing to MDS.
- Direct anti-proliferative effects: Directly inhibiting the growth of abnormal hematopoietic cells.
The patent's technical justification lies in the identification and optimization of these properties for the specific indication of MDS, especially within the defined patient subset.
What is the Competitive Patent Landscape for Thalidomide in MDS?
While CA2595988 is a key patent, the broader landscape involves other intellectual property considerations related to thalidomide and its use in MDS.
- Original Thalidomide Patents: Patents covering the synthesis and initial uses of thalidomide are long expired.
- Formulation Patents: Companies may hold patents on specific formulations of thalidomide that offer improved delivery, stability, or patient compliance. These could extend market exclusivity beyond the expiration of the active ingredient patent.
- Combination Therapy Patents: Patents claiming the use of thalidomide in combination with other therapeutic agents for MDS treatment may still be in force. This could limit the use of thalidomide in novel therapeutic regimens even after the expiration of CA2595988.
- Newer Therapies: The development of newer drugs specifically for MDS, such as lenalidomide (also a derivative of thalidomide and previously marketed by Celgene), has created a competitive landscape where thalidomide itself may be a less preferred or second-line option for certain patient groups. Lenalidomide held its own patent protection, which has also begun to expire, leading to generic competition.
- Manufacturing Process Patents: Patents related to specific, efficient, or cost-effective manufacturing processes for thalidomide could be a factor for generic manufacturers.
Analyzing these related patents is essential to determine the true freedom-to-operate for generic manufacturers seeking to enter the Canadian market for thalidomide in MDS.
What is the Market Impact of CA2595988's Expiration?
The expiration of CA2595988 on October 31, 2025, is expected to have a significant impact on the Canadian market for MDS treatments.
- Generic Entry: The expiration removes a primary IP hurdle, enabling generic manufacturers to seek Health Canada approval and market generic versions of thalidomide for MDS. This will likely lead to increased competition.
- Price Reduction: Increased competition from generic alternatives typically results in substantial price reductions for the drug. This could improve patient access and reduce healthcare system costs.
- Therapeutic Options: For MDS patients, particularly those with the del(5q) abnormality, generic thalidomide will become a more affordable treatment option.
- Market Shift: Depending on the price and availability of generics, thalidomide may regain market share or become a more competitive option against newer therapies or even its successor, lenalidomide, especially if lenalidomide's generic pricing is less aggressive or if specific patient profiles favor thalidomide.
- Generic Manufacturers: Companies specializing in generic drug manufacturing will likely target this market, requiring them to secure Abbreviated New Drug Submissions (ANDS) and demonstrate bioequivalence to the innovator product.
The precise market impact will be influenced by the speed of generic approvals, the pricing strategies of generic companies, and the existing clinical practice guidelines and physician prescribing habits for MDS treatment in Canada.
What is the Regulatory Pathway for Generic Thalidomide in Canada?
Following the expiration of CA2595988, generic manufacturers will need to navigate Health Canada's regulatory framework to bring their products to market.
- Abbreviated New Drug Submission (ANDS): Generic manufacturers will file an ANDS with Health Canada.
- Bioequivalence Studies: A key component of the ANDS is demonstrating bioequivalence of the generic product to the reference listed drug (RLD). This involves pharmacokinetic studies showing that the generic drug is absorbed into the bloodstream at the same rate and extent as the RLD.
- Quality and Manufacturing Data: The ANDS must also include comprehensive data on the generic drug's quality, manufacturing process, and stability, ensuring it meets Health Canada's stringent standards.
- Reference Listed Drug: The reference product for thalidomide in Canada would likely be the innovator product previously marketed by Celgene/Bristol Myers Squibb under its brand name for the approved indication.
- Patent Linkage: While CA2595988 will have expired, manufacturers must still be aware of any other potentially active patents (e.g., formulation, method of use) that could impact their freedom to market. The Canadian Patented Medicines (Notices of Compliance) Regulations provide a mechanism for patent holders to list their patents and for generic manufacturers to address these listings.
The regulatory review process typically takes several months to over a year, depending on the completeness of the submission and the complexity of the drug.
Key Takeaways
- Patent Expiration: Canada drug patent CA2595988, held by Celgene Corporation, expired on October 31, 2025.
- Core Innovation: The patent protected a method for treating myelodysplastic syndrome (MDS), specifically the 5q-syndrome, using thalidomide at specified dosages.
- Market Entry: The expiration removes a significant IP barrier, paving the way for generic thalidomide entry into the Canadian market for MDS treatment.
- Expected Impact: Generic entry is anticipated to lead to price reductions, increased patient access, and greater competition in the MDS treatment landscape.
- Regulatory Hurdles: Generic manufacturers must successfully navigate Health Canada's ANDS process, including demonstrating bioequivalence, to receive market authorization.
Frequently Asked Questions
-
Can thalidomide be prescribed for MDS in Canada before October 31, 2025?
While CA2595988 claims a method of treating MDS, the drug thalidomide may be available under specific compassionate use programs or if other patents covering its sale or formulation are also expired or invalid. However, commercial availability for this indication prior to patent expiration would be limited by the patent holder's exclusive rights.
-
What is the difference between MDS and 5q-syndrome?
Myelodysplastic syndrome (MDS) is a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, leading to peripheral cytopenias and an increased risk of transformation to acute myeloid leukemia. The 5q-syndrome is a specific subtype of MDS characterized by the presence of a deletion on the long arm of chromosome 5 (del(5q)).
-
Will generic thalidomide be interchangeable with brand-name thalidomide?
Upon approval by Health Canada, generic versions of thalidomide will be considered therapeutically equivalent and bioequivalent to the reference listed drug, meaning they can be substituted under standard pharmaceutical practices.
-
Are there other patents that could prevent generic thalidomide entry into Canada for MDS?
While CA2595988 is a key patent for the method of use, generic manufacturers must conduct a thorough freedom-to-operate analysis to identify and address any other potentially active patents covering formulations, manufacturing processes, or specific combination therapies.
-
What were the typical dosages for thalidomide in MDS as claimed by CA2595988?
The patent claims specified daily dosage ranges from about 50 mg to 400 mg, with specific examples including about 100 mg and about 200 mg daily doses.
Citations
[1] Celgene Corporation. (2005). Method for treating myelodysplastic syndrome. Canadian Patent CA2595988.
[2] Health Canada. (n.d.). Drug Development and Approval. Retrieved from https://www.canada.ca/en/health-canada.html (General source for regulatory information)
[3] National Cancer Institute. (n.d.). Myelodysplastic Syndromes (MDS) Treatment (PDQ®)–Health Professional Version. Retrieved from https://www.cancer.gov/ (General source for medical information on MDS)
